Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930044 | 0.81 | ALDH1A1 (0.40) | ALDH1A1TSHRGAAL3MBTL1DGAT1 | |
| SCHEMBL76832 | 0.80 | KDM4C (0.41) | KDM4CGAADGAT1 | |
| SCHEMBL7033296 | 0.78 | SHMT1 (0.37) | GAAL3MBTL1MAPTARKDM4E | |
| SCHEMBL21834933 | 0.78 | KDM4C (0.39) | KDM4CGAADGAT1 | |
| SCHEMBL16296168 | 0.78 | KDM4C (0.39) | KDM4CGAADGAT1 | |
| SCHEMBL4783072 | 0.77 | ALDH1A1 (0.30) | ALDH1A1DGAT1 | |
| SCHEMBL8906594 | 0.77 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1DGAT1 | |
| SCHEMBL7770065 | 0.77 | ALDH1A1 (0.30) | ALDH1A1DGAT1 | |
| SCHEMBL27693596 | 0.77 | KDM4C (0.47) | KDM4CALDH1A1TSHRGAAKDM4E | |
| SCHEMBL25848572 | 0.77 | KDM4C (0.38) | KDM4CALDH1A1TSHRGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560929-B1 | PROCESS FOR PREPARING 6,7-UNSATURATED-7-CARBAMOYL MORPHINANE DERIVATIVE, AND INTERMEDIATE | SHIONOGI & CO (JP) | 2021-05-19 | — | — | EP | disclosed |
| EP-3560929-A2 | CRYSTALLINE 6,7-UNSATURATED-7-CARBAMOYL MORPHINANE DERIVATIVE, AND METHOD FOR PRODUCING SAME | Shionogi & Co., Ltd (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-2639234-B1 | CRYSTALLINE 6,7-UNSATURATED-7-CARBAMOYL MORPHINANE DERIVATIVE, AND METHOD FOR PRODUCING SAME | SHIONOGI & CO (JP) | 2019-07-03 | — | — | EP | disclosed |
| CN-109415355-A | Benzdioxan derivative and its medicinal usage | 奥赖恩公司 | 2019-03-01 | — | — | CN | disclosed |
| US-9951082-B2 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9951082-B2 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20180072748-A1 | CRYSTAL OF 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | SHIONOGI & CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072748-A1 | CRYSTAL OF 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | SHIONOGI & CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180072748-A1 | CRYSTAL OF 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | SHIONOGI & CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9902732-B2 | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same | SHIONOGI & CO., LTD. (JP) | 2018-02-27 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-6962937-B2 | Imidazolidine derivatives, their preparation and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1373249-B1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTIINFLAMATORY AGENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1414444-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2004-05-06 | — | — | EP | disclosed |
| US-6680333-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIALLERGENS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-20 | — | — | US | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003011288-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VLA-4 ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | VCAM1, ITGA4, ITGA1 | KDM4C 2162/4885ALDH1A1 594/4885TSHR 495/4885 |
| US-20180072748-A1 | CRYSTAL OF 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVE AND METHOD FOR PRODUCING THE SAME | FASN, ALOX5, CASP7 | KDM4C 3486/4885ALDH1A1 1010/4885TSHR 4577/4885 |
| US-20030109497-A1 | Novel imidazolidine derivatives, their preparation and their use | VCAM1, ITGA1, ITGA4 | KDM4C 2032/4885ALDH1A1 819/4885TSHR 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.